Overcoming tumor antigen heterogeneity in CAR-T cell therapy for malignant mesothelioma (MM)
Abstract
<jats:p>Malignant mesothelioma (MM) is a rare, aggressive solid tumor with limited therapeutic options and poor therapeutic response. The role of immunotherapy in MM is now well established and therapeutic options, such as checkpoint inhibitors, are increasingly being approved. Chimeric antigen receptor (CAR)-T cell therapy is successfully implemented in several hematologic cancers, but currently has inadequate effect in solid tumors, owing to several limitations, such as trafficking and infiltration, limited T cell persistence and exhaustion, the immunosuppressive TME and tumor antigen heterogeneity. The lack of uniform and universal expression of tumor-associated antigens (TAAs) on tumor cells, as well as TAA heterogeneity following tumor editing post-therapy, are issues of significant importance to CAR-T cell and associated antigen-targeting therapies. Our review discusses the concept of tumor antigen heterogeneity in MM, the consequences for CAR-T cell therapies and the strategies to overcome it.</jats:p>
Collections
Subject
Antigen heterogeneity
chimeric antigen receptor (CAR) T cells
mesothelioma
tumor-associated
antigens (TAAs)
bystander effect
epitope spreading
tumor microenvironment
FIBROBLAST ACTIVATION PROTEIN
PLEURAL MESOTHELIOMA
PHASE-II
PLUS IPILIMUMAB
TARGET ANTIGEN
OPEN-LABEL
RECEPTORS
EFFICACY
AFFINITY
IMMUNOTHERAPY
Research team
Thor Onco Immuno Group
Language
eng
Date accepted
2022-07-18
License start date
2022-01-01
Citation
Journal of Cancer Metastasis and Treatment, 2022, 8 (5),
Publisher
OAE PUBLISHING INC
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.
Brown, JS; Sundar, R; Lopez, J (2018-02)The idea that chemotherapy can be used in combination with immunotherapy may seem somewhat counterproductive, as it can theoretically eliminate the immune cells needed for antitumour immunity. However, much preclinical ... -
Emerging biomarkers for PD-1 pathway cancer therapy.
Lim, JS; Sundar, R; Chénard-Poirier, M; Lopez, J; Yap, TA (2017-01)The field of immuno-oncology has witnessed unprecedented success in recent years, with several PD=1 and PD-L1 inhibitors obtaining US FDA registration and breakthrough drug therapy designation in multiple tumor types. ... -
Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain, L; Larkin, J (FUTURE MEDICINE LTD, 2016-06-01)